Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the medical research outsourcing and chemical preparations sectors showed positive growth, while hospitals and blood products faced declines [2][13]. - The report notes that the innovative drug licensing transactions in China exceeded $60 billion in the first quarter of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. Important Industry News - The NMPA has launched a three-year "Spring Rain Action" to promote the transformation of clinical innovation achievements in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has received FDA approval, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has been approved by the FDA, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, becoming the first of its kind domestically [46]. Investment Suggestions - The report suggests focusing on innovative drug companies with core technology platforms and differentiated pipeline layouts, especially those expected to achieve positive catalysts at major academic conferences like AACR [5]. - It also recommends attention to the CXO/CDMO industry chain, which is expected to benefit from improved overseas R&D demand and order recovery [5].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

Core Viewpoint - The innovative drug sector is experiencing significant growth, with multiple companies seeing substantial stock price increases, indicating a bullish trend in the market [1]. Group 1: Stock Performance - Shuyatain's stock price increased by 14.66%, reaching 26.52 [2] - Other notable performers include Dizhe Pharmaceutical with a 10.70% increase, Baili Tianheng at 10.63%, and Huana Pharmaceutical at 10.33% [2] - In the Hong Kong market, Keystone Pharmaceuticals surged over 18%, while CSPC Pharmaceutical and Xiansheng Pharmaceutical rose by over 12% and 8%, respectively [3] Group 2: Market Trends - The overall trend in the innovative drug sector shows a strong upward movement, with several companies hitting their daily price limits [1] - The performance of stocks in both mainland and Hong Kong markets reflects a growing investor confidence in the pharmaceutical industry [3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The report highlights that the domestic policy environment is continuously releasing positive signals, with the 2026 government work report explicitly listing biomedicine as a "new pillar industry" [6][7] - The report indicates that the pharmaceutical and biotechnology industry index declined by 2.99%, underperforming the CSI 300 index, with medical consumables and in vitro diagnostics showing positive growth [5][15] - The report emphasizes the importance of focusing on "independent innovation" and "policy benefits" as the main investment themes in the pharmaceutical and biotechnology sector [7] Industry Review - The pharmaceutical and biotechnology industry index experienced a decline of 2.99%, ranking 14th among 31 primary industries, and underperformed the CSI 300 index, which declined by 0.88% [5][15] - Medical consumables and in vitro diagnostics had the highest growth rates of 1.42% and 0.93%, respectively, while medical devices and medical research outsourcing saw declines of 6.57% and 6.54% [5][15] - As of March 13, 2026, the industry’s PE (TTM overall method, excluding negative values) was 30.34x, down from 31.06x, indicating a downward trend in valuation [20] Important Industry News - The 2026 government work report has been released, emphasizing biomedicine as a "new pillar industry" and proposing to expand pilot programs in biotechnology and accelerate the development of innovative drugs and medical devices [25][26] - The "14th Five-Year Plan" has been published, mentioning the pharmaceutical industry multiple times, reinforcing support for innovative drugs and related sectors [25][26] - Notable approvals include the global first cAMP biased GLP-1 receptor agonist "Elnoglutide Injection" by Hangzhou Xianweida Biotech and a $30 billion investment by Eli Lilly in China [6][34][43] Investment Recommendations - The report suggests focusing on high-quality pharmaceutical assets with differentiated innovation capabilities and sustainable potential, particularly those benefiting from policy support and high-quality development of innovative drugs [7] - The investment themes should concentrate on companies with strong clinical advancement capabilities and global cooperation potential, as well as those benefiting from the optimization of review and approval processes and payment systems [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The report highlights that the domestic policy environment is continuously releasing positive signals, with the 2026 government work report explicitly listing biomedicine as a "new pillar industry" [6][25] - The report indicates that the pharmaceutical and biotechnology industry index declined by 2.99%, underperforming the CSI 300 index, with medical consumables and in vitro diagnostics showing positive growth [5][15] - The report emphasizes the importance of focusing on "independent innovation" and "policy benefits" as the main investment themes in the pharmaceutical and biotechnology sector [7] Industry Review - The pharmaceutical and biotechnology industry index experienced a decline of 2.99%, ranking 14th among 31 primary industries, and underperformed the CSI 300 index, which declined by 0.88% [5][15] - The valuation of the pharmaceutical and biotechnology industry as of March 13, 2026, is 30.34x (TTM overall method, excluding negative values), down from 31.06x in the previous period, indicating a downward trend [20] - Among the sub-industries, the top three in terms of PE (TTM overall method, excluding negative values) are vaccines (54.84x), hospitals (41.28x), and medical consumables (39.52x), while the lowest is pharmaceutical circulation (14.66x) [20] Important Industry News - The 2026 government work report has been released, emphasizing biomedicine as a "new pillar industry" and proposing to further expand pilot programs in biotechnology and accelerate the development of innovative drugs and medical devices [6][25] - The "14th Five-Year Plan" outlines multiple references to the pharmaceutical industry, reinforcing support for innovative drugs and related sectors [25][26] - Notable approvals include the global first cAMP biased GLP-1 receptor agonist "Elnoglutide Injection" by Hangzhou Xianweida Biotech and a $30 billion investment by Eli Lilly in China [6][33][42] Investment Recommendations - The report suggests focusing on high-quality pharmaceutical assets with differentiated innovation capabilities and sustainable potential, particularly those benefiting from the high-quality development of innovative drugs and supportive policies [7] - It is recommended to pay attention to innovative drug companies with strong clinical advancement capabilities and global cooperation potential, as their valuation systems are expected to upgrade from single product logic to platform logic [7]

证券代码：688197 证券简称：首药控股 公告编号：2026-005 首药控股（北京）股份有限公司 本次合作能否最终达成，以及其效果有赖于协议各方高度密切配合。根据 拟签署的相关补充协议约定，一次性收益分成采用分期支付方式。若正大 1 天晴未能在约定时间内支付款项，公司有权按照中国法律的规定采取相关 措施，维护公司合法权益，但仍存在相关款项回收延迟、引发法律纠纷甚 至交易失败的风险，进而影响公司当期收益及现金流稳定。此外，相关收 益需满足《企业会计准则》的确认条件，具体的确认时点和金额存在一定 不确定性；且最终的损益确认金额需根据交易相关税费以及相关补充协议 约定的支付条款进行核算，具体财务数据将以审计机构审定的结果为准。 公司于2026年3月3日召开第二届董事会战略委员会第四次会议及第二届董 事会第十二次会议，会议分别审议通过了《关于调整JAK2抑制剂类抗肿瘤新药 的合作研发模式的议案》。 关于调整JAK2抑制剂类抗肿瘤新药的合作研发模式的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 相关内容提示： 2013 ...

Group 1 - The company Shouyao Holdings announced on February 27 that board member Ms. Li Ting has applied to resign from her position on the second board of directors due to internal management arrangements from the shareholder Beijing Yizhuang International Investment Development Co., Ltd. After her resignation, she will no longer hold any position within the company [1] - In February, China's AI usage surpassed that of the United States for the first time, with four major models ranking among the top five globally, indicating a significant increase in domestic computing power demand [1]

证券代码：688197 证券简称：首药控股 公告编号：2026-004 首药控股（北京）股份有限公司 关于董事离任的公告 根据《中华人民共和国公司法》《首药控股（北京）股份有限公司章程》，李 庭女士辞去董事职务后，将不会导致公司董事会成员低于法定最低人数，不会影 响董事会的正常运作，其书面辞任报告自送达公司董事会时生效。李庭女士确认： 在担任董事期间，其与公司、董事会及各专门委员会无意见分歧，亦无任何与辞 1 近日，首药控股（北京）股份有限公司（下称"公司"）董事李庭女士根据 股东单位北京亦庄国际投资发展有限公司的内部管理安排，申请辞去公司第 二届董事会董事职务，辞任后不再担任公司任何职务。鉴于李庭女士的辞任 未导致公司董事成员低于法定最低人数，其辞任报告已送达公司董事会并生 效。 李庭女士确认：在任期间，其与公司、董事会及各专门委员会无意见分歧， 亦无任何与辞任有关的其他应提请公司董事会、股东和债权人注意的事宜。 任有关的其他应提请公司董事会、股东和债权人注意的事宜。 截至本公告披露日，李庭女士未直接或者间接持有公司股份，不存在任何应 履行而未履行的承诺事项；李庭女士亦将遵守《上海证券交易所科创板股票上市 ...

Group 1 - The core point of the article is that Shouyao Holdings (688197.SH) is currently experiencing a decline in stock price, closing at 36.73 yuan with a drop of 2.29%, indicating that the stock is in a state of underperformance since its IPO [1] - Shouyao Holdings was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 23, 2022, with an initial offering price of 39.90 yuan per share and a total of 37.18 million shares issued, representing 25.00% of the total share capital post-IPO [1] - The total funds raised by Shouyao Holdings during its IPO amounted to 1.483 billion yuan, with a net amount of 1.374 billion yuan after deducting issuance costs [1] - The company aimed to raise 2.0 billion yuan as stated in its prospectus, with plans to allocate the funds for innovative drug research and development projects, the establishment of a new drug R&D and industrialization base, and to supplement working capital [1] - The total issuance costs for Shouyao Holdings were 110 million yuan, with the lead underwriter, CITIC Securities, receiving 90.8957 million yuan in underwriting and sponsorship fees [1]

Core Viewpoint - Shouyao Holdings (688197.SH) is currently experiencing a decline in stock price, closing at 37.36 yuan with a drop of 3.84%, indicating it is in a state of post-IPO underperformance [1] Group 1: Company Overview - Shouyao Holdings was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 23, 2022, with an initial offering price of 39.90 yuan per share [1] - The company issued a total of 37.18 million shares, which represents 25.00% of the total share capital after the issuance [1] - The total funds raised from the IPO amounted to 1.483 billion yuan, with a net amount of 1.374 billion yuan after deducting issuance costs [1] Group 2: Fund Utilization - Shouyao Holdings intended to raise 2.0 billion yuan, which was planned to be allocated for innovative drug research and development projects, the establishment of a new drug R&D and industrialization base, and to supplement working capital [1] Group 3: Financial Details - The total issuance costs for Shouyao Holdings were 110 million yuan, with the lead underwriter, CITIC Securities Co., Ltd., receiving underwriting and sponsorship fees of 90.8957 million yuan [1]